Qiagen
Search results
Jun 6, 2024 · Learn about MorphoSys. A commercial-stage biopharmaceutical company that develops innovative medicines, aspiring to redefine how cancer is treated.
- About Us | MorphoSys
Find out more about MorphoSys, our leadership, our...
- MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates ...
Pelabresib plus ruxolitinib showed clinically meaningful...
- About Us | MorphoSys
MorphoSys AG is a German biopharmaceutical company founded in 1992. The company is headquartered near Munich , Germany , and has a wholly owned subsidiary, MorphoSys US Inc. , in Boston , Massachusetts, in the US.
Feb 5, 2024 · Novartis announces a voluntary public takeover offer for MorphoSys, a biopharmaceutical company developing innovative medicines in oncology. The transaction includes pelabresib, a late-stage BET inhibitor for myelofibrosis, and tulmimetostat, an early-stage EZH inhibitor for solid tumors or lymphomas.
MorphoSys is a company that develops and delivers innovative medicines for difficult-to-treat and debilitating types of cancers. Learn about its history, culture, leadership, responsibility and commitment to people living with cancer.
Nov 20, 2023 · MorphoSys AG announces positive results from Phase 3 study of pelabresib, a BET inhibitor, in combination with ruxolitinib for myelofibrosis patients. Pelabresib showed significant improvement in spleen volume reduction and symptom relief compared to placebo and ruxolitinib.
May 16, 2024 · Basel, 16 May 2024 – Today, Novartis BidCo AG, an (indirect) wholly owned subsidiary of Novartis AG, announced the result of its voluntary public takeover offer (the “Offer”) for the shares of MorphoSys AG (“MorphoSys”), including all shares represented by MorphoSys American Depositary Shares (“ADS”). As of the expiry of the ...
Feb 6, 2024 · Feb 6 (Reuters) - Drugmaker Novartis AG (NOVN.S) said it will acquire MorphoSys AG (MORG.DE), a developer of cancer treatments, for 2.7 billion euros ($2.9 billion), adding a promising rare bone...
